Synthesis and In Vitro Evaluation of Gold Nanoparticles Functionalized with Thiol Ligands for Robust Radiolabeling with $^{99m}$Tc

Adamantia Apostolopoulou 1,2*, Aristeidis Chiotellis 1, Evangelia-Alexandra Salvanou 1, Konstantina Makrypidi 1, Charalampos Tsoukalas 1, Fotis Kapiris 1, Maria Paravatou-Petsotas 1, Minas Papadopoulos 1, Ioannis C. Pirmettis 1,*, Przemyslaw Koziński 3, and Penelope Bouziotis 1,*

1 National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; madoapostol@gmail.com (A.A.); achiotel@rrp.demokritos.gr (A.C.); salvanou@rrp.demokritos.gr (E.-A.S.); kmakripidi@gmail.com (K.M.); ctsoukal@rrp.demokritos.gr (C.T.); fotiskp@gmail.com (F.K.); mparavatou@rrp.demokritos.gr (M.P.-P.); mspap@rrp.demokritos.gr (M.P.); ipirme@rrp.demokritos.gr (I.C.P.)
2 Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zographou, 15771 Athens, Greece
3 Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, Poland; p.kozinski@ichtj.waw.pl
* Correspondence: bouziot@rrp.demokritos.gr; Tel.: +30-2106503687

Abstract: Radiolabeled gold nanoparticles (AuNPs) have been widely used for cancer diagnosis and therapy over recent decades. In this study, we focused on the development and in vitro evaluation of four new Au nanoconjugates radiolabeled with technetium-$^{99m}$Tc via thiol-bearing ligands attached to the NP surface. More specifically, AuNPs of two different sizes (2 nm and 20 nm, referred to as Au(2) and Au(20), respectively) were functionalized with two bifunctional thiol ligands (referred to as L1H and L2H). The shape, size, and morphology of both bare and ligand-bearing AuNPs were characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS) techniques. In vitro cytotoxicity was assessed in 4T1 murine mammary cancer cells. The AuNPs were successfully radiolabeled with $^{99m}$Tc-carbonyls at high radiochemical purity (>95%) and showed excellent in vitro stability in competition studies with cysteine and histidine. Moreover, lipophilicity studies were performed in order to determine the lipophilicity of the radiolabeled conjugates, while a hemolysis assay was performed to investigate the biocompatibility of the bare and functionalized AuNPs. We have shown that the functionalized AuNPs developed in this study lead to stable radiolabeled nanoconstructs with the potential to be applied in multimodality imaging or for in vivo tracking of drug-carrying AuNPs.

Keywords: gold nanoparticles; $^{99m}$Tc-carbonyls; radiolabeling; cytotoxicity; MTT; hemolysis assay

1. Introduction

Nanoparticles are materials with dimensions at the nanometer scale (1–100 nm) and over the last decades have been widely used in theranostic applications, thus playing an effective role in the diagnosis and therapy of cancer by offering multiple possibilities in oncology [1]. The aim of nanotechnology is to allow efficient accumulation of the nanodrug in the target organ or tissue, regardless of the method and the route of administration, while limiting unwanted toxic effects due to the administration of high concentrations of conventional anticancer drugs.

In particular, gold nanoparticles (AuNPs) have been extensively investigated for the development of dual-modality imaging agents, as well as for theranostic applications due to their unique physicochemical properties, ease of surface functionalization with different chemical entities, low toxicity, and biocompatibility. They also present high sensitivity and
can be detected even at low concentrations [1–3]. Gold nanoparticles are synthesized by various methods, including the reduction of gold ions (Au\(^{3+}\)) to produce gold atoms (Au\(^{0}\)) by using reducing agents such as amino acids, UV light, or citrate, but also eco-friendly synthetic processes in aqueous solutions rather than organic solvents, where ascorbic acid (AA) has been used instead of traditional reductants [4–6]. The use of AuNPs in diagnostic applications is based on the passive targeting of the tumor site via the enhanced permeability and retention (EPR) effect, where the nanoparticles, due to their small size, extravasate into tumors through leaky vasculatures, where they are retained due to poor lymphatic drainage. AuNPs can also reach the disease site via active targeting, where targeting ligands (such as peptides or monoclonal antibodies) attached to the nanoparticle surface recognize specific receptors overexpressed on the surface of tumor cells, resulting in enhanced accumulation in the targeted organ [7,8].

In order to investigate the in vivo kinetics of AuNPs, these can be radiolabeled with a wide variety of radionuclides. However, NP radiolabeling is associated with some significant disadvantages. For example, some radiolabeling modifications have been shown to affect the physicochemical properties of the nanoparticles. Moreover, AuNPs present many shapes, sizes, and morphologies, leading to a huge variety of radiolabeled compounds. Most importantly, targeting efficiency of the radiolabeled NPs is lost if the radiolabel does not remain associated with the NPs for a sufficient period of time [9].

For diagnosis, short-lived gamma- or positron-emitting radionuclides, including technetium-99m (\(^{99m}\)Tc), gallium-68 (\(^{68}\)Ga), iodine-123 (\(^{123}\)I), indium-111 (\(^{111}\)In), fluorine-18 (\(^{18}\)F), and copper-64 (\(^{64}\)Cu), are extensively used for radiolabeling AuNPs [9–18]. \(^{99m}\)Tc is the most commonly used radionuclide in diagnostic imaging, due to its ideal nuclear characteristics, such as emission of low-energy γ-rays (140 keV) and suitable half-life (6.02 h), as well as its convenient availability from \(^{99}\)Mo/\(^{99m}\)Tc generators [19,20]. Labeling via the [\(^{99m}\)Tc][\(\text{Tc(H}_2\text{O)}_3\text{(CO)}_3\)]\(^+\) carbonyl core is a very efficient way of radiolabeling with \(^{99m}\)Tc and was first introduced by Alberto et al. in 1998 [21].

AuNPs can also be radiolabeled with therapeutic radioisotopes such as actinium-225 (\(^{225}\)Ac), iodine-131 (\(^{131}\)I), lutetium-177 (\(^{177}\)Lu), rhenium-186 (\(^{186}\)Re), rhenium-188 (\(^{188}\)Re), astatine-211 (\(^{211}\)At), etc. Radionuclides used in therapy should have suitable half-lives, long enough to deliver the radiation dose to the targeted organ/tissue. Additionally, they must emit α- and β-particles [9,22–24]. As in diagnostic applications, the nanoparticles are accumulated in the tumor via the EPR effect or due to active targeting. Their smaller size and surface chemistry affect their cellular uptake, thus they are currently being investigated for delivering chemotherapeutic agents into the tumor. The use of AuNPs in radiotherapy has increased the survival rate up to 86% compared to radiotherapy without AuNPs (20% survival rate) [25]. However, some nanoparticles present long-circulating properties, which may increase the radiation dose to the non-targeted organs, such as the spleen [3].

Various studies in the literature have reported the use of \(^{99m}\)Tc-labeled AuNPs as potential multifunctional agents and have shown interesting results, depending on their physicochemical characteristics and surface functionalization. Alberto et al. presented a new multifunctional ligand for AuNPs for direct labeling with \(^{99m}\)Tc-carboxyls consisting of a terminal thiol group as an anchor for the AuNP surface, a polyethylene glycol (PEG) linker, and 2,3-diaminopropionic acid (DAP) chelator for the [\(^{99m}\)Tc][\(\text{Tc(CO)}_3\)]\(^+\) core (HS-PEG-DAP). In addition, a small molecule inhibitor for the prostate specific membrane antigen (PSMA) was conjugated to the coating ligand to introduce a targeting function for prostate cancer [18]. Gómez-Oliván et al. functionalized AuNPs with hydrazinonicotinamide-GGC (HYNIC-GGC) for labeling with \(^{99m}\)Tc and c[RGDfK(C)] peptides for tumor targeting by means of spontaneous reaction of the thiol groups of cysteine [7]. Another example of functionalizing AuNPs via thiol groups of cysteine was provided by Torres–García et al., who evaluated the in vitro potential of \(^{99m}\)Tc-labeled and \(^{177}\)Lu-labeled AuNPs conjugated to Tat(49–57)-Lys\(^3\)-bombesin peptides (\(^{99m}\)Tc/\(^{177}\)Lu-AuNP-Tat-BN) as a plasmionic photothermal therapy and targeted radiotherapy system in PC3 prostate cancer cells [14].
A multifunctional radiopharmaceutical, such as the one described herein, ([\textsuperscript{\textit{99m}}Tc]Tc-AuNP may function simultaneously as both a radiodiagnostic imaging agent and a thermal ablation system (i.e., localized heating after laser irradiation) in cancer cells [26,27]. The aim of this initial research study was to functionalize the surfaces of AuNPs of two different sizes (2 nm and 20 nm, referred to as Au\textsubscript{(2)}NPs and Au\textsubscript{(20)}NPs, respectively), with two thiol ligands (referred to as L\textsubscript{1}H and L\textsubscript{2}H), which allow direct labeling with [\textit{99m}Tc]-carbonyls. These ligands contain a thiol group, which acts as an anchor for the surface of the AuNPs, as well as an [NNN] donor atom set for robust coordination of the [\textsuperscript{\textit{99m}}Tc][Tc(CO)\textsubscript{3}]\textsuperscript{+} group.

The labeling procedure requires surface modification of the AuNPs with each ligand, resulting in Au\textsubscript{(2)}NPs-L\textsubscript{1}, Au\textsubscript{(2)}NPs-L\textsubscript{2}, Au\textsubscript{(20)}NPs-L\textsubscript{1}, and Au\textsubscript{(20)}NPs-L\textsubscript{2}, and incubation with the semi aqua ion [\textsuperscript{\textit{99m}}Tc][Tc(H\textsubscript{2}O)\textsubscript{3}(CO)\textsubscript{3}]\textsuperscript{+} as the last step. [\textsuperscript{\textit{99m}}Tc][Tc(H\textsubscript{2}O)\textsubscript{3}(CO)\textsubscript{3}]\textsuperscript{+} is an ion with three coordination sites. Its water molecules can be substituted, which means that a huge variety of mono-, bi-, and tridentate ligands can be used and radiolabeled with the tricarbonyl core [18,20]. In this study, the two tridentate thiol ligands L\textsubscript{1}H and L\textsubscript{2}H (shown in Figure 1) were used: (i) to stabilize the AuNPs by forming strong Au-S bonds [12] and (ii) to form a complex with the [\textsuperscript{\textit{99m}}Tc][Tc(CO)\textsubscript{3}]\textsuperscript{+} core via the three nitrogen atoms that acted as donor atoms [19,20].

![Figure 1. The two tridentate thiol ligands used in this study: (A) L\textsubscript{1}H and (B) L\textsubscript{2}H.](image)

After functionalization of AuNPs with the two thiol ligands and radiolabeling with [\textsuperscript{\textit{99m}}Tc][Tc(H\textsubscript{2}O)\textsubscript{3}(CO)\textsubscript{3}]\textsuperscript{+}, in vitro stability in human serum and in cysteine and histidine solutions was examined in order to evaluate the stability of the formed radiolabeled complexes. Moreover, cytotoxicity studies using the MTT assay were carried out to evaluate the toxicity of the nanoconjugates. Finally, lipophilicity experiments were performed to determine the lipophilicity of the radiolabeled nanoparticles, while a hemolysis assay helped us examine the biocompatibility of bare and functionalized AuNPs.

### 2. Materials and Methods

#### 2.1. Chemical Reagents

\textsuperscript{\textit{99m}}Tc is a gamma emitter with a photon energy of 140 keV, which requires radiation protection precautions during handling to reduce the risk of harm. All work associated with radiolabeling procedures was conducted in a licensed radiochemistry facility, where such experiments could be safely conducted.

All reagents and solvents were of chemical grade and used without further purification. Dimethylsulfoxide (DMSO, > 99.5%) was purchased from Aldrich Chemical (St. Louis, MO, USA). Acetonitrile (CH\textsubscript{3}CN > 99.5%) was purchased from Carlo Erba (Val-de-Reuil, France). Trifluoroacetic acid (TFA > 99%) was purchased from Alfa Aesar (Loughborough, UK). Human serum was purchased from Sigma Aldrich (St. Louis, MO, USA). L\textsubscript{1}H and compound 1 were synthesized according to published procedures with slight modifications [28,29]. Nuclear magnetic resonance (NMR) spectra were recorded in DMSO-d\textsubscript{6} on a Bruker Avance DRX 500 MHz spectrometer at room temperature. The measured chemical shifts are reported in $\delta$ (ppm) and the residual signal of the solvent was used as the internal calibration standard (CDCl\textsubscript{3} $\textsuperscript{1}H = 7.26$ ppm, $\textsuperscript{13}C = 77.16$ ppm). All $\textsuperscript{13}C$ NMR spectra were measured with complete proton decoupling. Data of NMR spectra were recorded as follows: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad signal. The coupling constant $J$ is reported in hertz (Hz). HPLC was performed using a Waters 600 Controller pump, a Waters 996 Photodiode Array detector, and a γ-RAM radioactivity detector to measure radioactive flow on a Jupiter C4 Column (150 × 4.60 mm, 5 µm, 300 Å,
Phenomenex, Torrance, CA, USA). The UV detection wavelength was set at 220 nm for all experiments. $^{99m}$Tc was eluted as Na$[^{99m}$Tc$]TcO_4$ from a commercial $^{99m}$Mo/$^{99m}$Tc generator (Mallinckrodt Medical B.V.). The HPLC solvents of analytical grade were filtered through 0.22 mm membrane filters (Millipore, Milford, MA, USA). Radioactivity measurements were conducted in a dose calibrator (Capintec, Ramsey, NJ, USA). Samples for lipophilicity studies were measured on a Packard COBRA II Auto-Gamma Counter (Ramsey, MN, USA).

The 4T1 cell line was acquired from the cell bank of the Laboratory of Radiobiology, Institute of Nuclear and Radiological Sciences and Technology, Energy, and Safety, NCSR “Demokritos”, Athens, Greece. RPMI was used as medium for the cultures and was purchased from BioWest (Nuaillé, France) and the MTT reagent [3-(4,5 –dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was obtained from Applichem (Darmstadt, Germany). For the optical density measurements, a LabSystems Multiskan RC Microplate Reader (Thermo Fisher Scientific, Waltham, MA, USA) was used.

The AuNPs were characterized by transmission electron microscopy (TEM, LEO 912B). The apparent hydrodynamic diameter and zeta potential ($\zeta$) were measured by dynamic light scattering (DLS, Malvern, UK).

2.2. Synthesis of Gold Nanoparticles

Gold nanoparticles with 20 nm diameter (Au$^{(20)}$) were synthesized by the modified Turkevich method [4]. For this purpose, 40 mg of gold(III) chloride trihydrate was dissolved in 100 mL of distilled water and heated under reflux in a round bottom flask. Next, 112 mg of trisodium citrate dihydrate previously dissolved in 10 mL of distilled water were rapidly added to the solution of gold(III) chloride and the mixture was further was for 15 min. After cooling down the gold nanoparticle solution, the flask was wrapped with aluminum foil and stored at 4–8 $^\circ$C. The size of Au$^{(20)}$ was checked by TEM and DLS techniques. The prepared solution of Au$^{(20)}$ had great stability and exhibited a deep red color.

Gold nanoparticles with 2 nm diameter (Au$^{(2)}$) were synthesized as described before [30]. A solution of chloroaauric acid (78.8 mg in 10 mL of methanol) was added to the aqueous solution of 4-mercaptobenzoic acid (MBA 104.85 mg in 8 mL), the pH was adjusted to 13 using NaOH, and the solution was left at room temperature for 24 h. In the next step, to the solution of Au/MBA 86.67 mL of methanol, 246.67 mL of water and 3.33 mL of a 0.25 M sodium borohydride were added and the mixture was left for 18 h at RT. The solution color changed from pale yellow to black. In the last step, 350 mL of methanol was added to the above solution and the mixture was centrifugated at 8000 $\times$ g for 10 min. The supernatant was removed and the precipitate was suspended in 16 mL of 10 mM ammonium acetate. The size of the synthesized Au$^{(2)}$ was checked by TEM.

2.3. Synthesis of Ligands

Synthesis of trityl intermediate 2: A solution of quinoline-2-carbaldehyde (0.49 g, 3.13 mmol) in DCM (1 mL) was added dropwise within 5 min to a mixture of 2-(tritylthio)ethanamine 1 (0.5 g, 1.57 mmol) and NaBH(OAc)$_3$ (1 g, 4.7 mmol) in DCM (4 mL) at 0 $^\circ$C. The reaction was allowed to reach room temperature, at which point the brown-colored suspension turned into a deep brown slurry and was left to stir overnight. The next day, the reaction was quenched with sat. NaHCO$_3$ at 0 $^\circ$C and was stirred for 3 h, allowing it to reach room temperature. The reaction was then transferred to a funnel, diluted with CHCl$_3$ (60 mL), and washed with sat. NaHCO$_3$ (1 × 50 mL), water (1 × 50 mL) and brine (1 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered, and evaporated to dryness under vacuum. The crude red–brown oil (1.56 g) was purified by gravity column chromatography using CHCl$_3$/AcOEt/Et$_3$N 80:20:1 to afford the product (3, 725 mg, 77%) as a red foamy solid. $^1$H NMR (CDCl$_3$, ppm): 8.13–8.07 (m, 2H, Quin$_H$), 8.07–8.01 (m, 2H, Quin$_H$), 7.81–7.65 (m, 6H, Quin$_H$), 7.54–7.47 (m, 2H, Quin$_H$), 7.40–7.32 (m, 6H, STrt), 7.23–7.10 (m, 9H, STrt), 3.89 (s, 4H, NCH$_2$ Quin$_H$), 2.68 (t, $J$ = 6.7 Hz, 2H, NCH$_2$CH$_2$STrt), 2.41 (t, $J$ = 6.7 Hz, 2H, NCH$_2$CH$_2$STrt). $^{13}$C NMR (CDCl$_3$, ppm): 160.31,
147.61, 145.00, 136.38, 129.67, 129.42, 129.14, 127.89, 127.59, 127.52, 126.63, 126.22, 121.29, 66.68, 61.15, 53.67, 30.09.

**Synthesis of L\textsubscript{2}H:** TFA (3.4 mL, 44.8 mmol) was added dropwise within 10 min to a solution of 2 (412 mg, 0.68 mmol) and triethylsilane (0.34 mL, 2.12 mol) in DCM (10 mL) at −10 °C. The deep-red colored reaction was stirred at −10 °C for 5 min and then was allowed to reach room temperature, where it was stirred for 2 h. Volatiles were then removed under vacuum at 30 °C and the red/brown solid was dissolved in CHCl\textsubscript{3} (30 mL) and washed with sat. NaHCO\textsubscript{3} (1 × 25 mL), water (1 × 25 mL), and brine (1 × 25 mL). The organic layer was dried over Na\textsubscript{2}SO\textsubscript{4}, filtered, and evaporated to dryness under vacuum. The crude product (0.5 g) was purified by flash column chromatography using CHCl\textsubscript{3}/AcOEt/Et\textsubscript{3}N 8:2:0.1 to afford L\textsubscript{2}H (216 mg, 88%) as a yellow solid (Figure 2).

1H NMR (CDCl\textsubscript{3}, ppm): 8.16–8.11 (m, 2H, Quin\textsubscript{H}), 8.09–8.02 (m, 2H, Quin\textsubscript{H}), 7.82–7.65 (m, 6H, Quin\textsubscript{H}), 7.54–7.47 (m, 2H, Quin\textsubscript{H}), 4.06 (s, 4H, NCH\textsubscript{2}Quin\textsubscript{H}), 2.90 (t, \(J = 6.6\) Hz, 2H, NC\textsubscript{H}\textsubscript{2}CH\textsubscript{2}SH), 2.71 (t, \(J = 6.6\) Hz, 2H, NCH\textsubscript{2}CH\textsubscript{2}SH), 1.61 (br, 1H, CH\textsubscript{2}S\textsubscript{H})

13C NMR (CDCl\textsubscript{3}, ppm): 159.99, 147.66, 136.56, 129.58, 129.15, 127.65, 127.52, 126.37, 121.30, 61.29, 57.45, 22.64.

![Figure 2. Synthesis of bifunctional ligand L\textsubscript{2}H. The synthesis of L\textsubscript{1}H has been previously reported in the literature [28, 29].](image-url)

2.4. **Functionalization of Gold Nanoparticles**

Prior to the radiolabeling process, both Au\textsuperscript{(2)} and Au\textsuperscript{(20)} were each surface-functionalized with both thiol ligands (L\textsubscript{1}H, L\textsubscript{2}H) in two separate procedures, leading to four nanoparticle complexes: Au\textsuperscript{(2)}L\textsubscript{1}, Au\textsuperscript{(2)}L\textsubscript{2}, Au\textsuperscript{(20)}L\textsubscript{1}, and Au\textsuperscript{(20)}L\textsubscript{2}. All samples were prepared according to the same procedure, as follows. Briefly, 0.001 nmol of AuNPs were mixed with 0.8 µmol of each ligand (0.21 mg of L\textsubscript{1}H and 0.29 mg of L\textsubscript{2}H dissolved in DMSO) and stirred overnight. Then, the samples were centrifugated at 2300 \(\times\) g for 20 min and the supernatant was carefully removed. The purified AuNPs were ready for radiolabeling, as described below in Section 2.9 (Figure 3).

2.5. **Cell Cultures**

The 4T1 murine mammary cancer cell line was used for the biological evaluation of the synthesized compounds. Cells were grown in RPMI-1640 medium (RPMI) at a pH of 7.4, supplemented with 10% fetal bovine serum (FBS), 100 U/mL of penicillin, 2 mM glutamine, and 100 µg/mL of streptomycin. Cell cultures were maintained in flasks and were grown at 37 °C in a humidified atmosphere of 5% CO\textsubscript{2} in air. Subconfluent cells were detached using a 0.25% trypsin-0.53 mM ethylenediaminetetraacetic acid (EDTA) solution, and the subcultivation ratio was 1:8–1:10.
Figure 3. Functionalization of AuNPs with thiol ligands and radiolabeling with $[^{99m}Tc][Tc(H_2O)_3(CO)_3]^+$. 

2.6. Cytotoxicity Studies

Cytotoxicity evaluation of bare AuNPs (namely Au$^{(2)}$ and Au$^{(20)}$) and ligand-functionalized AuNPs (namely Au$^{(2)}L_1$, Au$^{(2)}L_2$, Au$^{(20)}L_1$, and Au$^{(20)}L_2$) was carried out using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric assay. This method is based on the reduction of yellow MTT tetrazolium salt to purple formazan crystals by active cells in mitochondria and catalyzed by dehydrogenase enzymes. The formed purple formazan crystals can be solubilized and the absorbance of this purple solution can be quantified and determined by spectrophotometry at a certain wavelength. This transformation is only possible in viable cells, because dead cells are unable to metabolize MTT, thus leading to reduced absorbance. The metabolic activity of the cells is proportional to the color density of the purple formazan crystals. For these reasons, MTT assay can be used as an indicator for cell viability and cytotoxicity [31,32].

4T1 cells were seeded in a 96-well plate at a density of $10^4$ cells per well and incubated overnight at 37 °C for attachment. The following day, increasing concentrations of Au$^{(2)}$, Au$^{(20)}$ and ligand-functionalized Au$^{(2)}L_1$, Au$^{(2)}L_2$, Au$^{(20)}L_1$, and Au$^{(20)}L_2$ (0.0625, 0.125, 0.25, 0.5, 1 and 2 nM) were added to the exponentially growing cells in 4 replicates. The control group consisted of cells without the compound. After 24 h of incubation, the medium was replaced with MTT solution ($C_{MTT} = 1$ mg/mL) in RPMI and was added to each well. The cells were further incubated for 4 h. After removing the MTT solution, 100 µL of isopropanol was added to each well. Following thorough mixing, the absorbance was measured at 560 nm using an ELISA reader. Finally, the mean value of the optical density (OD) of the four replicates and the percentage of the OD was calculated with the following equation:

$$\text{OD} \% = \left( \frac{\text{mean value of the OD of four replicates}}{\text{OD of control}} \right) \times 100$$

Each assay was performed in triplicate.

2.7. Hemolysis Assay

The lab members participating in this study provided their consent for the use of their blood samples in these experiments. The donors underwent blood sampling following the approval of the Ethics Committee of the NCSR “Demokritos”. All experiments were carried out in accordance with relevant guidelines and regulations. According to our protocol,
blood was drawn by venipuncture from two healthy donors and was centrifugated at 1000 \times g for 5 min to separate the plasma from the red blood cells (RBCs). After removing the plasma, the RBCs were washed 3 times with PBS (0.01 M, pH 7.4) free of calcium and magnesium. Solutions of bare and ligand-functionalized AuNPs were prepared at different concentrations in PBS (0.5–1–2 nM). Then, 285 \mu L of each sample was added to 15 \mu L of RBCs. As the negative control, we used 285 \mu L of PBS from the last centrifugation with 15 \mu L of RBCs, whereas 10 \mu L of TRITON X (10%) mixed with 275 \mu L PBS and 15 \mu L of RBCs served as the positive control in our study. Finally, all the samples were incubated at 37 °C for 3 h and were centrifugated once again at 1000 \times g for 5 min. One hundred microliters of the supernatants of all the samples were placed in 96-well plates and the OD was measured at 450 nm in a LabSystems Multiskan RC Microplate Reader [33]. The hemolysis ratio was calculated with the following equation:

\[
\text{Hemolysis ratio} \% = \frac{(\text{OD of AuNPs} - \text{OD of negative control})}{(\text{OD of positive control} - \text{OD of negative control})} \times 100
\]

2.8. Preparation of the Precursor [99mTc][Tc(H2O)3(CO)3]⁺

The labeling precursor [99mTc][Tc(H2O)3(CO)3]⁺ was prepared as described in the literature [34]. Briefly, a vial containing 4 mg Na2CO3, 20 mg sodium tartrate and 7 mg NaBH4 was sealed and CO gas was purged for 2 min prior to addition of 1 mL Na[99mTc]TcO4 eluate obtained from a ⁹⁹Mo/⁹⁹mTc generator. The vial was heated at 115 °C for 30 min and, at the end of the reaction, was left to cool at room temperature. Finally, the precursor was brought to pH 6.5–7 through the addition of HCl 1 M. The formation of the precursor [99mTc][Tc(H2O)3(CO)3]⁺ was determined by reverse-phase HPLC (RP-HPLC) on a C18-RP column with a MeOH/0.1% TFA and H2O/0.1% TFA gradient over 30 min at a flow rate of 1 mL/min. The radioactivity of the precursor was measured using a dose calibrator. τR HPLC (γ detector): [99mTc][Tc(H2O)3(CO)3]⁺: 4–6 min, [99mTc][TcO4]⁻: 3.0 min. Radiochemical yield (RCY) > 95%.

2.9. Radiolabeling with [99mTc][Tc(H2O)3(CO)3]⁺

After functionalization, the AuNPs were radiolabeled with 100 \mu L [99mTc][Tc(H2O)3(CO)3]⁺ (0.8–2 mCi) by incubation at 70 °C for 2 h. Radiochemical yield was determined by HPLC, applying a linear gradient system from 0% B to 100% B at 25 min, where solvent A was H2O/0.1% TFA and solvent B was ACN/0.1% TFA, at a flow rate of 1 mL/min. Subsequently, the samples were purified by centrifugation at 2300 \times g for 20 min (Figure 2).

2.10. In Vitro Stability Studies

After purification, we examined the in vitro stability of the radiolabeled nanostructures in human serum and in cysteine/histidine solutions of the formed radiolabeled complexes in order to evaluate their in vivo stability.

2.10.1. Human Serum Stability

For human serum stability assessment, 50 \mu L of each of the radiolabeled complexes (100–300 \mu Ci) were challenged against 450 \mu L human serum and the mixture samples were incubated at 37 °C for 1 h and 24 h. Afterwards, 100 \mu L of each mixture were treated with 200 \mu L ethanol at different timepoints (1 h, 24 h). The samples were centrifugated at 450 \times g for 10 min to precipitate serum proteins. The supernatants were removed and analyzed by HPLC [10].

2.10.2. Cysteine–Histidine Stability

For cysteine–histidine stability assessment, 50 \mu L samples of each of the radiolabeled complexes (100–300 \mu Ci) were challenged against 450 \mu L of cysteine and histidine solutions (0.02 M). Then, the samples were incubated at 37 °C for 1 h and 24 h and analyzed by HPLC [35].
2.11. Lipophilicity Studies

The lipophilicity of the radiolabeled complexes was determined by calculating the partition coefficient (P) with the shake-flask method. Briefly, in a centrifuge tube, 1 mL of 1-octanol and 1 mL PBS (0.01 M, pH 7.4) were mixed with 1–2 µCi of each of the radiolabeled complexes. The samples were vortexed for 1 min and the radioactivity of the aliquots (200 µL) of each phase was counted in a gamma counter. The partition coefficient was calculated according the following equation. The results were expressed as logP. The procedure was repeated three times [35].

\[
P = \frac{\text{counts/mL on the 1-octanol phase}}{\text{counts/mL on the PBS phase}}
\]

3. Results and Discussion

3.1. Synthesis and Characterization of Gold Nanoparticles

The synthesized Au\(^{(2)}\) and Au\(^{(20)}\) nanoparticles were characterized by TEM and DLS methods. The results are presented in Table 1 and in Figure 4. The obtained Au\(^{(20)}\) nanoparticles were characterized by TEM and DLS methods. In the case of Au\(^{(2)}\), due to the small size, only TEM analysis was possible. The results of size and zeta potential of nanoparticles are presented in Table 1. The negative zeta potential values for naked AuNPs, as well as AuNPs decorated with L\(_2\)H, indicate that there was no tendency for the particles to aggregate. The difference between the zeta potential of non-modified AuNPs and L\(_2\)H additionally confirms that surface modification was achieved. DLS measurements show that Au\(^{(20)}\)L\(_1\) were five times bigger in size after surface modification and positive zeta potential.

|                         | Hydrodynamic Diameter (nm)   | Zeta Potential (mV) |
|-------------------------|------------------------------|---------------------|
|                         | Au\(^{(20)}\)                | 20.9                |
|                         | Au\(^{(20)}\) L\(_1\)        | 124.48              |
|                         | Au\(^{(20)}\) L\(_2\)        | 41.2                |
|                         | Au\(^{(20)}\)                | –33.5               |
|                         | Au\(^{(20)}\) L\(_1\)        | 12.2                |
|                         | Au\(^{(20)}\) L\(_2\)        | –16.8               |

Figure 4. TEM images of (A) Au\(^{(2)}\) and (B) Au\(^{(20)}\) nanoparticles before surface functionalization.
3.2. Synthesis of Ligands

To enable high-affinity $^{99m}$Tc labeling of AuNPs, we started this study by synthesizing two bifunctional tridentate [NNN] ligands termed L$_1$H and L$_2$H. Each carries a thiol moiety that can robustly conjugate with AuNPs via an Au-S bond while the [NNN] donor atom set remains exposed for $^{99m}$Tc coordination. The L$_1$H and L$_2$H chelating ligands incorporate amine and aromatic N-heterocycles donors (pyridine for L$_1$H and quinoline for L$_2$H), for which previous studies on the coordination chemistry of the M(CO)$_3$ core has shown that they are highly effective [36,37]. L$_1$H was synthesized by following a published procedure with slight modifications [28], while L$_2$H was synthesized as described above (both synthetic procedures are shown in Figure 2). Cysteamine hydrochloride was reacted with triphenylmethanol to afford the S-trityl intermediate 1 [29]. Reaction of 1 with quinoline-2-carbaldehyde under reductive amination conditions yielded 2 in good yield (77%) and the trityl protecting group was subsequently cleaved with TFA/Et$_3$SiH to afford L$_2$H (88%).

3.3. MTT Assay

The MTT assay was conducted to evaluate the cytotoxicity of both bare and functionalized AuNPs against 4T1 murine mammary cancer cells. The murine 4T1 mammary epithelial carcinoma represents a widely used model of triple-negative breast cancer (TNBC) [38]. The 4T1 tumor shares many features of human stage IV breast cancer, including metastatic behavior in mice, with spontaneous metastasis to lymph nodes, lung, liver, bone, and brain while the primary tumor is still growing [39]. Furthermore, for our future prospects on assessing the therapeutic potential of nanoparticles radiolabeled with beta- or alpha-emitting radionuclides, the 4T1 cell line provides an interesting tumor model with spontaneous metastases to various sites (e.g., lung, bone, etc.) [40].

The samples were exposed to different concentrations of AuNPs for 24 h. The results of the experimental data are summarized in Figures 5 and 6 and indicate that Au$^{(2)}$ and Au$^{(20)}$ revealed almost no toxicity, even at the highest tested concentration. In the case of the nanoparticles functionalized with L$_1$H, Au$^{(2)}$L$_1$ revealed significant toxicity, with cell viability decreasing gradually from 77% at the lowest concentration (0.0625 nM) to 6% at the highest concentration (2 nM), whereas Au$^{(20)}$L$_1$ revealed similar toxicity patterns, with cell viability decreasing from 96% to 17%. On the contrary, the nanoparticles functionalized with L$_2$H showed less toxicity in 4T1 cells since the recorded cell viability values ranged between 91–77% for Au$^{(2)}$L$_2$ and 87–84% for Au$^{(20)}$L$_2$ at the lowest (0.0625 nM) and the highest tested concentrations (2 nM), respectively. In addition, the cytotoxicity of the plain thiol ligands L$_1$H and L$_2$H was also evaluated and the results are summarized in Figures S1–S17 (Supplementary Materials). In accordance with the recorded results of AuNPs, for ligand L$_1$H, the recorded cell viability values gradually decreased from 47% to 7%, while in the case of L$_2$H, the levels of viability fluctuated around 70% at all tested concentrations, indicating that the presence of Au$^{(2)}$ and Au$^{(20)}$ nanoparticles did not alter the biological effect of the ligands on the cells. It is worth mentioning that, in all cases, the presence of pyridine-bearing bifunctional ligand L$_1$H on the surface of both Au$^{(2)}$ and Au$^{(20)}$ induced a more profound cytotoxic effect in 4T1 cells than the quinoline-bearing ligand L$_2$H, a fact that may be related to the existing differences in structure, size, stereochemistry, etc., and this requires further investigation.
Figure 5. MTT assay of 4T1 cells treated with different concentrations of Au\textsuperscript{(2)}, Au\textsuperscript{(2)}L1, and Au\textsuperscript{(2)}L2.

Figure 6. MTT assay of 4T1 cells treated with different concentrations of Au\textsuperscript{(20)}, Au\textsuperscript{(20)}L1 and Au\textsuperscript{(20)}L2.
3.4. Hemolysis Assay

The hemolysis assay allowed us to evaluate the interactions between RBCs and the developed AuNPs. When a compound is toxic for RBCs, the tonicity of RBCs changes. In our case, 285 µL of PBS from the last centrifugation with 15 µL of RBCs was used as the negative control, whereas 10 µL TRITON X 10% (which is known to cause hemolysis) with 275 µL PBS and 15 µL of RBCs was used as the positive control. The effect of hemolysis caused by AuNPs is shown in Figure 7. The results after incubation at all variable concentrations of AuNPs indicated that our samples did not cause hemolysis, which confirms the biocompatibility of both bare and functionalized AuNPs.

![Figure 7. Hemolytic effect of: (A) Au(2) and Au(20), (B) Au(2)L1 and Au(20)L1, and (C) Au(2)L2 and Au(20)L2 at different tested concentrations (0.5 nM, 1 nM, and 2 nM). Positive control: 10 µL TRITON X 10% + 275 µL PBS + 15 µL of RBCs; negative control: 285 µL PBS +15 µL of RBCs.](image)

3.5. Functionalization and Radiolabeling of AuNPs

The functionalization of Au(2) and Au(20) with L1H and L2H and the consequent radiolabeling procedures have been described above. The aim of the functionalization was to provide an adequate chelator for the robust radiolabeling of Au(2) and Au(20) with \[^{99m}\text{Tc}\]([Tc(H2O)3(CO)3]+. After the functionalization, strong Au-S bonds were formed between the AuNPs and the thiol groups of both ligands. Thiol groups are considered to be the most important type of molecule to stabilize any size of AuNPs [18,20,41]. For radiolabeling, a mixture of \[^{99m}\text{Tc}\]([Tc(H2O)3(CO)3]+ and functionalized AuNPs was incubated at 70 °C for 2 h. The semi aqua ion \[^{99m}\text{Tc}\]([Tc(H2O)3(CO)3]+ has three available coordination sites and the metal center is primarily found in the oxidative state +1, so after radiolabeling,
the water molecules were substituted with the three nitrogen atoms (as donor atoms) of the thiol ligands, thus forming a $^{99m}$Tc complex (Figure 3). Radiolabeling yield was found to be approximately 85%. After purification by centrifugation, radiochemical purity for all samples was >95%, which remained stable for at least 24 h post-purification. The results are summarized in Figure 8. All the corresponding HPLC traces can be seen in the Supplementary Materials section.

3.6. In Vitro Stability Studies

The radiolabeled complexes exhibited satisfactory in vitro stability in human serum, and negligible transchelation in the presence of cysteine and histidine, which indicates the robust binding of $^{99m}$Tc with the AuNPs, thus enhancing their potential as SPECT imaging agents or for use in in vivo tracking applications. Our results are in accordance with work performed by other groups [35,42]. The results are summarized in Figure 9 The corresponding HPLC traces can be seen in the Supplementary Materials section.

3.7. Lipophilicity Studies—Determination of Partition Coefficient

The partition coefficients (P) were determined using the shake-flask method as described above and are expressed as logP. The AuNPs functionalized with L$_1$ exhibited hydrophilic behavior, whereas the AuNPs functionalized with L$_2$, indicated higher lipophilicity, which may be attributed to the more lipophilic character of L$_2$H due to the quinoline ring. The results are presented in Table 2.
Figure 9. In vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$, $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$, $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_1$, and $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_2$ at 1 h and 24 h post-radiolabeling.

Table 2. Partition Coefficient of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$, $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$, $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_1$ and $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_2$.

| Radiolabeled Complex | logP  |
|----------------------|-------|
| $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$ | $-0.94 \pm 0.24$ |
| $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_1$ | $-0.85 \pm 0.16$ |
| $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$ | $2.39 \pm 0.17$ |
| $[^{99m}\text{Tc}]\text{Tc-Au}^{(20)}\text{L}_2$ | $2.23 \pm 0.20$ |

4. Conclusions

Au$^{(2)}$ and Au$^{(20)}$ nanoparticles were surface-functionalized with two different [NNN]-bearing ligands capable of coordinating the $[^{99m}\text{Tc}][\text{Tc(CO)}_3]^+$ core, which also contains a thiol group that acts as an anchor for the surface of the AuNPs. Radiolabeling was quick and efficient, with the resulting nanoconstructs exhibiting negligible transchelation of the radiolabel, as demonstrated by the cysteine/histidine challenge.

While robust radiolabeling was afforded for both nanoparticles functionalized with the thiol-bearing ligands L$_1$H and L$_2$H, further investigation on the in vivo kinetics of Au$^{(2)}$ and Au$^{(20)}$ nanoparticles will be performed with the L$_2$-functionalized AuNPs, due to their better in vitro toxicity profile.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nano11092406/s1, Figure S1: HPLC Diagrams representing the radiochemical purity of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$ at (A) 1 h and (B) 24 h post-incubation, Figure S2: HPLC Diagrams representing the in vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$ in cysteine solution at (A) 1 h and (B) 24 h post-incubation, Figure S3: HPLC Diagrams representing the in vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$ in histidine solution at (A) 1 h and (B) 24 h post-incubation, Figure S4: HPLC Diagrams representing the in vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_1$ in human serum at (A) 1 h and (B) 24 h post-incubation, Figure S5: HPLC Diagrams representing the radiochemical purity of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$ at (A) 1 h and (B) 24 h post-incubation, Figure S6: HPLC Diagrams representing the in vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$ in cysteine solution at (A) 1 h and (B) 24 h post-incubation, Figure S7: HPLC Diagrams representing the in vitro stability of $[^{99m}\text{Tc}]\text{Tc-Au}^{(2)}\text{L}_2$ in histidine solution at (A) 1 h and (B) 24 h post-incubation.
post-incubation, Figure S8: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(2)L2 in human serum at (A) 1 h and (B) 24 h post-incubation, Figure S9: HPLC Diagrams representing the radiochemical purity of [99mTc]Tc-Au(20)L1 at (A) 1 h and (B) 24 h post-incubation, Figure S10: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L1 in cysteine solution at (A) 1 h and (B) 24 h post-incubation, Figure S11: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L1 in histidine solution at (A) 1 h and (B) 24 h post-incubation, Figure S12: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L2 in human serum at (A) 1 h and (B) 24 h post-incubation, Figure S13: HPLC Diagrams representing the radiochemical purity of [99mTc]Tc-Au(20)L2 at (A) 1 h and (B) 24 h post-incubation, Figure S14: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L2 in cysteine solution at (A) 1 h and (B) 24 h post-incubation, Figure S15: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L2 in histidine solution at (A) 1 h and (B) 24 h post-incubation, Figure S16: HPLC Diagrams representing the in vitro stability of [99mTc]Tc-Au(20)L2 in histidine solution at (A) 1 h and (B) 24 h post-incubation, Figure S17: MTT Assay of 4T1 cells treated with different concentrations of L1H and L2H. The tested ligand concentrations correspond to the concentrations of the AuNPs used in the MTT Assay.

Author Contributions: Conceptualization, P.K., A.C. and P.B.; methodology, A.A., E.-A.S., K.M. and F.K.; validation, P.K., M.P., I.C.P., C.T., M.P.-P. and P.B.; investigation, A.A., E.-A.S., K.M. and F.K.; resources, P.K., M.P., I.C.P. and P.B.; writing—original draft preparation, A.A., E.-A.S., A.C. and P.K.; writing—review and editing, all authors; supervision, P.K., A.C., C.T. and P.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was co-financed by Greece and the European Union (European Social Fund–ESF) through the operational program “Human Resources Development, Education, and Lifelong Learning” in the context of the project “Strengthening Human Resources Research Potential via Doctorate Research” (MIS-5000432), implemented by the State Scholarships Foundation (IKY). Part of this research was also funded by statutory activity of the Institute of Nuclear Chemistry and Technology, Warsaw, Poland.

Institutional Review Board Statement: All the donors participated in this study provided their written, informed consent. The donors underwent blood sampling following the approval of the Ethics Committee of the NCSR “Demokritos”.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The laboratory of P. Petrou and S. Kakabakos is acknowledged for use of the LabSystems Multiskan RC Microplate Reader. The authors gratefully acknowledge B. Movroidi and M.A. Karageorgou for valuable scientific discussions and remarks.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ali, H.S.; El-Haj, B.M.; Saifullah, S.; Kawish, M. Gold Nanoparticles in Cancer Diagnosis and Therapy; Elsevier: Amsterdam, The Netherlands, 2019; ISBN 9780128169605.
2. Same, S.; Aghanejad, A.; Nakhjavani, S.A.; Barar, J.; Omidi, Y. Radiolabeled theranostics: Magnetic and gold nanoparticles. BioImpacts 2016, 6, 169–181. [CrossRef]
3. Connor, D.M.; Broome, A.M. Gold Nanoparticles for the Delivery of Cancer Therapeutics, 1st ed.; Elsevier: Amsterdam, The Netherlands, 2018; Volume 139, ISBN 9780128141694.
4. Turkевич, J.; Stevenson, P.C.; Hillier, J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss. Faraday Soc. 1951, 11, 55–75. [CrossRef]
5. Liu, K.; Han, L.; Zhuang, J.; Yang, D.P. Protein-directed gold nanoparticles with excellent catalytic activity for 4-nitrophenol reduction. Mater. Sci. Eng. C 2017, 78, 429–434. [CrossRef]
6. Wang, X.; Yang, D.P.; Huang, P.; Li, M.; Li, C.; Chen, D.; Cui, D. Hierarchically assembled Au microspheres and sea urchin-like architectures: Formation mechanism and SERS study. Nanoscale 2012, 4, 7766–7772. [CrossRef]
7. Danhier, F.; Feron, O.; Prétat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135–146. [CrossRef]
8. Farokhzad, O.C.; Langer, R. Impact of Nanotechnology on Hair Attributes. ACS Nano 2009, 3, 1–7.
9. Trent, R.J. Molecular Medicine; Elsevier: Amsterdam, The Netherlands, 2012; ISBN 9780123814517.

10. Morales-Avilla, E.; Ferro-Flores, G.; Ocampo-García, B.E.; De León-Rodríguez, L.M.; Santos-Cuevas, C.L.; García-Becerra, R.; Medina, L.A.; Gómez- Oliván, L. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to [RGDfK(C) for molecular imaging of tumor α(v)β3 expression. Bioconjug. Chem. 2011, 22, 913–922. [CrossRef] [PubMed]

11. Zhu, J.; Chin, J.; Wängler, C.; Wängler, B.; Lennox, R.B.; Schirrmacher, R. Rapid 18F-labeling and loading of PE-Grafted gold nanoparticles for in vivo applications. Bioconjug. Chem. 2014, 25, 1143–1150. [CrossRef] [PubMed]

12. Ng, Q.K.T.; Olariu, C.I.; Yaffe, M.; Taelman, V.F.; Marineck, N.; Krause, T.; Meier, L.; Walter, M.A. Indium-111 labeled gold nanoparticles for in-vivo molecular targeting. Biomaterials 2014, 35, 7050–7057. [CrossRef]

13. Yim, M.S.; Hwang, Y.S.; Bang, J.K.; Jung, D.W.; Kim, J.M.; Yi, G.R.; Lee, G.; Ryu, E.K. Morphologically homogeneous, pH-responsive gold nanoparticles for non-invasive imaging of HeLa cancer. Nanomed. Nanotechnol. Biol. Med. 2021, 34, 102394. [CrossRef]

14. Pretze, M.; van der Meulen, N.P.; Wängler, C.; Schibli, R.; Wängler, B. Targeted 64Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging. J. Label. Compd. Radiopharm. 2019, 62, 471–482. [CrossRef]

15. Zhao, Y.; Sultan, D.; Detering, L.; Cho, S.; Sun, G.; Pierce, R.; Wooley, K.L.; Liu, Y. Copper-64-alloyed gold nanoparticles for cancer imaging: Improved radiolabel stability and diagnostic accuracy. Angew. Chemie Int. Ed. 2014, 53, 156–159. [CrossRef] [PubMed]

16. Chilig, L.E.; Leonte, R.A.; Patrascu, M.E.B.; Ion, A.C.; Tuta, C.S.; Raicu, A.; Manda, G.; Niculae, D. In vitro binding kinetics study of gold nanoparticles functionalized with 68Ga-DOTA conjugated peptides. J. Radioanal. Nucl. Chem. 2017, 311, 1485–1493. [CrossRef]

17. Jiménez-Mancilla, N.; Ferro-Flores, G.; Santos-Cuevas, C.; Ocampo-García, B.; Luna-Gutiérrez, M.; Azorín-Vega, E.; Isaac-Olivé, K.; Camacho-López, M.; Torres-García, E. Multifunctional targeted therapy system based on 99mTc/177Lu-labeled gold nanoparticles-Tat(49-57)-Lys3-bombesin internalized in nuclei of prostate cancer cells. J. Label. Compd. Radiopharm. 2013, 56, 663–671. [CrossRef] [PubMed]

18. Felber, M.; Bauwens, M.; Mateos, J.M.; Imstepf, S.; Mottaghy, F.M.; Alberto, R. 99mTc Radiolabeling and Biological Evaluation of Nanoparticles Functionalized with a Versatile Coating Ligand. Chem. A Eur. J. 2015, 21, 6090–6099. [CrossRef] [PubMed]

19. Dilworth, J.R.; Parrott, S.J. The biomedical chemistry of technetium and rhenium. Chem. Soc. Rev. 1998, 27, 43–55. [CrossRef]

20. Mazzi, U.; Schibli, R.; Pietzsch, H.J.; Künstler, J.U.; Spies, H. Technetium-99m Pharmaceuticals; Zolle, I., Ed.; Springer: Berlin/Heidelberg, Germany, 2007; pp. 7–58. [CrossRef]

21. Alberto, R.; Schibli, R.; Egli, A.; Schubiger, A.P.; Abram, U.; Kaden, T.A. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of [99mTc(OH2)(CO3)]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 1999, 120, 7987–7988. [CrossRef]

22. Dziawi, L.; Majkowska-Plip, A.; Gawel, D.; Godlewksa, M.; Pruszyński, M.; Jastrzębski, J.; Was, B.; Bilewicz, A. Trastuzumab-modified gold nanoparticles labeled with 211At as a prospective tool for local treatment of HER2-positive breast cancer. Nanomaterials 2019, 9, 632. [CrossRef]

23. Dziawi, L.; Koźmiński, P.; Mečyterska-Wielgosz, S.; Pruszyński, M.; Łyczko, M.; Was, B.; Celichowski, G.; Grobelny, J.; Jastrzębski, J.; Bilewicz, A. Gold nanoparticle bioconjugates labelled with 211At for targeted alpha therapy. RSC Adv. 2017, 7, 41024–41032. [CrossRef]

24. Salvanou, E.A.; Stellas, D.; Tsoukalas, C.; Mavroidi, B.; Paravatou-petsofas, M.; Kalogeropoulos, N.; Xanthopoulos, S.; Denat, F.; Laurent, G.; Bazzi, R.; et al. A proof-of-concept study on the therapeutic potential of α particles radiolabeled with the alpha-emitter actinium-225. Pharmaceutics 2020, 12, 188. [CrossRef]

25. Cai, W.; Gao, T.; Hong, H.; Sun, J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol. Sci. Appl. 2008, 1, 17–32. [CrossRef]

26. Grosges, T.; Barchiesi, D. Gold nanoparticles as a photothermal agent in cancer therapy: The thermal ablation characteristic length. Molecules 2018, 23, 1316. [CrossRef] [PubMed]

27. Mieszawska, A.J.; Mulder, W.J.M.; Fyad, Z.A.; Cormode, D.P. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 2013, 10, 831–847. [CrossRef]

28. Lazarova, N.; Babich, J.; Valliant, J.; Schaffer, P.; James, S.; Zubieta, J. Thiol- and thioether-based bifunctional chelates for the labeling of biomolecules. J. Am. Chem. Soc. 2013, 135, 6763–6770. [CrossRef] [PubMed]

29. Vishwanatha, T.M.; Bergamaschi, E.; Dömling, A. Sulfur-Switch Ugi Reaction for Macrocyclic Disulfide-Bridged Peptidomimetics. Org. Lett. 2017, 19, 3195–3198. [CrossRef] [PubMed]

30. Ackerson, C.J.; Jazdinsky, P.D.; Sexton, J.Z.; Bushnell, D.A.; Kornberg, R.D. Synthesis and bioconjugation of 2 and 3 nm-diameter iron oxide nanoparticles. Bioconjug. Chem. 2010, 21, 214–218. [CrossRef] [PubMed]

31. Karageorgou, M.A.; Vranjš-Djuric, S.; Radović, M.; Lyberopoulou, A.; Antić, B.; Rouchota, M.; Gazouli, M.; Loudos, G.; Xanthopoulos, S.; Sideratou, Z.; et al. Gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropylene-1,1-diphosphonic acid as a potential PET/MR imaging agent: A proof-of-concept study. Contrast Media Mol. Imaging 2017, 2017, 6951240. [CrossRef]

32. Papadopoulou, S.; Kolokithas-ntoukas, A.; Salvanou, E.; Gaitanis, A.; Xanthopoulos, S.; Avgoustakis, K.; Gazouli, M.; Paravatou-petsofas, M.; Tsoukalas, C.; Bakandritos, A.; et al. Chelator-Free / Chelator-Mediated Radiolabeling of Colloidally Stabilized Iron Oxide Nanoparticles for Biomedical Imaging. Nanomaterials 2021, 11, 1677. [CrossRef]
33. Nikolopoulou, S.G.; Boukos, N.; Sakellis, E.; Efthimiadou, E.K. Synthesis of biocompatible silver nanoparticles by a modified polyol method for theranostic applications: Studies on red blood cells, internalization ability and antibacterial activity. *J. Inorg. Biochem.* **2020**, *211*, 111177. [CrossRef]

34. Schibli, R.; La Bella, R.; Alberto, R.; Garcia-Garayoa, E.; Ortner, K.; Abram, U.; Schubiger, P.A. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. *Bioconjug. Chem.* **2000**, *11*, 345–351. [CrossRef]

35. Paparidis, G.; Akrivou, M.; Tsachouridou, V.; Shegani, A.; Vizirianakis, I.S.; Pirmettis, I.; Papadopoulos, M.S.; Papagiannopoulou, D. Synthesis and evaluation of 99mTc/Re-tricarbonyl complexes of the triphenylphosphonium cation for mitochondrial targeting. *Nucl. Med. Biol.* **2018**, *57*, 34–41. [CrossRef]

36. Banerjee, S.R.; Levadala, M.K.; Lazarova, N.; Wei, L.; Valliant, J.F.; Stephenson, K.A.; Babich, J.W.; Maresca, K.P.; Zubieta, J. Bifunctional Single Amino Acid Chelates for Labeling of Biomolecules with the \( \{\text{Tc(CO)}_3\}^+ \) and \( \{\text{Re(CO)}_3\}^+ \) Cores. Crystal and Molecular Structures of [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)C\(_4\)H\(_3\))NH(CH\(_2\)CO\(_2\))CH\(_2\)]Br (X = Y = 2-pyridylmethyl), [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)C\(_4\)H\(_3\))NH(CH\(_2\)CO\(_2\))CH\(_2\)CH\(_2\)]Br (X = Y = 2-pyridylmethyl), [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)C\(_4\)H\(_3\))NH(CH\(_2\)CO\(_2\))CH\(_2\)CH\(_2\)CH\(_3\)Br (X = Y = 2-(1-methylimidazolyl)methyl), [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br, [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br, [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br, [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br, [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br, [ReBr(CO)\(_3\)(C\(_5\)H\(_4\)NCH\(_2\)NH(CH\(_2\)C\(_4\)H\(_3\))S)]Br. *Inorg. Chem.* **2002**, *41*, 6417–6425. [CrossRef]

37. Gasser, G.; Neumann, S.; Ott, I.; Seitz, M.; Heumann, R.; Metzler-Nolte, N. Preparation and biological evaluation of Di-heteroorganometallic-containing PNA bioconjugates. *Eur. J. Inorg. Chem.* **2011**, 2011, 5471–5478. [CrossRef]

38. Dexter, D.L.; Kowalski, H.M.; Blazar, B.A.; Fligiel, Z.; Vogel, R.; Gloria, H.; Heppner, H. Heterogeneity of Tumor Cells from a Single Mouse Mammary Tumor. *Cancer Res.* **1978**, *38*, 3174–3181. [PubMed]

39. Krystofiak, E.S.; Matson, V.Z.; Steeber, D.A.; Oliver, J.A. Elimination of tumor cells using folate receptor targeting by antibody-conjugated, gold-coated magnetite nanoparticles in a murine breast cancer model. *J. Nanomater.* **2012**, 2012, 431012. [CrossRef] [PubMed]

40. Heppner, G.H.; Miller, F.R.; Shekhar, P.V.M. Nontransgenic models of breast cancer. *Breast Cancer Res.* **2000**, *2*, 331–334. [CrossRef] [PubMed]

41. Kogan, M.J.; Olmedo, I.; Hosta, L.; Guerrero, A.R.; Cruz, L.J.; Albericio, F. Peptides and metallic nanoparticles for biomedical applications. *Nanomedicine* **2007**, *2*, 287–306. [CrossRef] [PubMed]

42. Psimadas, D.; Oliveira, H.; Thevenot, J.; Lecommandoux, S.; Bouziotis, P.; Varvarigou, A.D.; Georgoulias, P.; Loudos, G. Polymeric micelles and vesicles: Biological behavior evaluation using radiolabeling techniques. *Pharm. Dev. Technol.* **2014**, *19*, 189–193. [CrossRef]